Sutro BiopharmaSTRO
Recorded

Sutro Biopharma Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration29 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Speaker

Thanks, everyone, for joining us here with Sutro today. CEO Jane and Jonathan, the Head of Clinical Development. I do want to spend some time getting more into the platform because I think it's really important to what you do and part of what makes you guys differentiated versus a lot of other ADCs. Maybe to start, if you could just briefly introduce the company, yourselves, and how your platform differentiates versus other ADC platforms.

Jane ChungCEO

First, thank you, Laura, for the opportunity to be here and share the update on Sutro. I'm Jane Chung. I've been the CEO since last March when we made a strategic pivot to our next-generation ADC pipeline. We have a very unique platform. For folks who have followed the Sutro story for some time, because our company has been around for 20 years, we have this cell-free technology that enables us to really optimize every component of an ADC. In fact, the design features are not bound by a cell membrane. That's why it's coined cell-free. But it allows us to ultra-design these things. Antibody ADCs are very complex structures that include an antibody, a linker, a payload. We actually employ non-natural amino acids on top of that.

Jane ChungCEO

All of these design decisions really help us really fine-tune what we think is going to make important decisions that can improve the outcomes for patients. I think what we're trying to do with our technology here is to make drugs that are not easily made with conventional ADCs. We will talk about this later, but the dual payload ADCs require us to really fine-tune not just one linker payload, but two linker payloads on the same antibody. That's not an easy thing to do because it's not just about adding more toxicity, because that can lead to more toxicity, but really just fine-tuning the ratios, the positioning of the linker payloads so that it's internalized and leads to better performance for these medicines.

Jane ChungCEO

We're very excited about the platform and our strategy right now since I've taken the lead of the company has been really taking our pipeline, which now consists of both single payload and dual payload ADCs. The single payloads will validate our optimized linker payload chemistry and non-natural positioning, and be able to kind of, once we're able to maintain and demonstrate lower hematology toxicity or neutropenia, then we can combine two or more linker payload systems in a safe way to be able to deliver even more potency and better outcomes for patients.

Speaker

Since we are on the topic of platform, maybe getting a little bit more into the dual payload ADC approach. We, your investors, innately just think about one-to-one ratios when you talk about dual payload. Can you stress a little bit more how differentiated you guys are on this front and your ability to, I believe, with the dual payload, you will be getting an IND for in the near future Yes scale the different cytotoxic payloads.

Jane ChungCEO

Yeah. So, our dual payload ADCs, our 227 program, which is targeting PTK7. It is actually not only a dual payload, but it is also a DAR10. It is like the first dual payload that is actually going higher with the DAR beyond eight exatecans. The whole premise behind dual payloads in and of itself is to overcome resistance to all the single payload ADCs that are currently in development. What is next after Topo1 resistance? We saw this field sort of emerging when we made the pivot last year, that we saw the field moving from first-generation tubulin payloads to a second-generation Topo1 payloads. We then asked the question, what is next?

Jane ChungCEO

Because resistance will happen. We believe that resistance happens not driven by the target, as evidenced by the fact that HER2 patients actually get treated with multiple treatments along their journey, but actually driven by the payload or chemotherapy. Combination chemotherapy has been a standard of care in many of these disease states. We know that delivering combination targeted therapy will be important. It is not just about adding to add more toxicity. It is about fine-tuning these ratios, not just a one plus one, but it could be a one plus two or one plus three. You have to be able to bake that off. The chemistry capabilities of our platform enable us to do that so that we could find the right therapeutic window that is both efficacious but also safe.

Speaker

Mm-hmm. A lot of this has to do with the use of the non-natural amino acids, correct?

Jane ChungCEO

Yes. Thank you for pointing that out because I think it's a point that's an element that's a little less appreciated. We use non-naturals to If you think about conventional ADCs, the linker payloads are attached to or conjugated to cysteines that naturally occur on an antibody. Those are not necessarily made for conjugation, so they have a tendency for linker payloads to fall off. We use these non-naturals to actually pick the right positioning so that they're more protected within the ADCs from cleavage in the circulation, as well as stabilized our linker system to also provide more stability for the program so that it gets to the destination, which is tumor cells, and then is cleaved by the enzymes within the tumor.

Speaker

As far as flexibility to use the optimal linker, use the optimal antibody, you guys seem to have a lot of flex here. You're not bound to just one type of linker, one type of antibody, one type of payload, or two specific types of payload. You can apply this to many different types of biology, correct?

Jane ChungCEO

Yes. I think it allows us to go after really complex targets that are really hard to do with conventional means. The flexibility gives us sort of a competitive edge. When you're trying to just bolt things onto inherent structures, it doesn't always work. But the ability to kind of have the flexibility of design is really the unique feature of the platform. Anything you'd like to add there, Jonathan?

Jonathan FawcettHead of Clinical Development

Absolutely. I mean, absolutely, Jamie. You've put it so neatly. I mean, with combination chemo, which is essentially what dual payloads are, there was a lot of optimization to get the dosing regimens right.

Jonathan FawcettHead of Clinical Development

How would that not play out in the dual payload ADC space?

Jonathan FawcettHead of Clinical Development

Yeah. The tunability of the platform is important.

Jonathan FawcettHead of Clinical Development

I mean, I sat through a large number of discovery seminars at Sutro where we discussed the ratios. In fact, they didn't just discuss them, they made them. I mean, there were a whole variety made.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day